Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Connect Biopharma Holdings (CNTB) Enterprise Value (2023 - 2025)

Connect Biopharma Holdings' Enterprise Value history spans 3 years, with the latest figure at -$54.7 million for Q3 2025.

  • For Q3 2025, Enterprise Value changed N/A year-over-year to -$54.7 million; the TTM value through Sep 2025 reached -$54.7 million, changed N/A, while the annual FY2024 figure was -$93.7 million, 11.31% up from the prior year.
  • Enterprise Value for Q3 2025 was -$54.7 million at Connect Biopharma Holdings, up from -$71.8 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$54.7 million in Q3 2025 and bottomed at -$105.7 million in Q4 2023.
  • The 3-year median for Enterprise Value is -$84.0 million (2025), against an average of -$82.0 million.
  • The largest YoY upside for Enterprise Value was 11.31% in 2024 against a maximum downside of 11.31% in 2024.
  • A 3-year view of Enterprise Value shows it stood at -$105.7 million in 2023, then rose by 11.31% to -$93.7 million in 2024, then skyrocketed by 41.58% to -$54.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Enterprise Value are -$54.7 million (Q3 2025), -$71.8 million (Q2 2025), and -$84.0 million (Q1 2025).